MAGEA6 Engages a YY1‐Dependent Transcription to Dictate Perineural Invasion in Colorectal Cancer
Advanced Science · 2025-07 · 12 (25)
DOI: 10.1002/advs.202501119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 27.03.2025. Verfasst von Hao Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, P. R. China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, YY1 Transcription Factor, Neoplasm Proteins, Antigens, Neoplasm. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Shanghai Pudong New Area Health Commission, Chinese Society of Clinical Oncology.
Abstract (Originalsprache)
Perineural invasion (PNI), characterized by tumor cells surrounding and invading nerves, is associated with poor prognosis in colorectal cancer (CRC). Understanding the mechanisms of PNI is crucial for developing targeted therapies to impede tumor progression. In this study, clinical information and transcriptome data are obtained from the TCGA database. Stable MAGEA6 knockdown CRC cell lines are established to investigate the impact of MAGEA6 on CRC malignancy. Immunohistochemical staining is used to assess the clinical significance of MAGEA6. Rectal orthotopic and sciatic nerve invasion models are employed to verify the role of MAGEA6 in PNI. Schwann cells (SCs) infiltration and recruitment by CRC cells are assessed using ssGSEA and co‐culture experiments. The results reveal that MAGEA6 is a key regulator of PNI, with its expression correlating with poor prognosis. MAGEA6 knockdown reduces CRC cell migration, invasion, and PNI ability. Moreover, CRC cells recruit SCs, with CXCL1 promoting SCs migration. Mechanistically, MAGEA6 inhibits YY1 ubiquitination, stabilizing YY1 expression and enhancing SC recruitment via YY1‐mediated CXCL1 transcription. These findings suggest that MAGEA6 enhances CRC invasiveness and PNI by stabilizing YY1, which upregulates CXCL1 secretion and promotes SC recruitment. This interaction underscores the critical role of MAGEA6 in PNI and highlights a potential therapeutic target in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, P. R. China.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
- Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
ORCID-Profile: Junli Xue
Förderung
- Natural Science Foundation of China
- Shanghai Pudong New Area Health Commission
- Chinese Society of Clinical Oncology
- Healthcare Talents Elite Program of Shanghai Pudong New Area
- Academic Leaders Training Program of Pudong Health Bureau of Shanghai
- National Natural Science Foundation of China
Zitieren
APA
Wang, H., He, K., Huo, R., Li, W., Zhang, S., Jiang, L. J., Wu, H., Yu, M., Jiang, S. H., & Xue, J. (2025). MAGEA6 Engages a YY1‐Dependent Transcription to Dictate Perineural Invasion in Colorectal Cancer. Advanced Science, 12(25). https://doi.org/10.1002/advs.202501119
Vancouver
Wang H, He K, Huo R, Li W, Zhang S, Jiang LJ, et al. MAGEA6 Engages a YY1‐Dependent Transcription to Dictate Perineural Invasion in Colorectal Cancer. Advanced Science. 2025;12(25). doi:10.1002/advs.202501119
BibTeX
@article{Wang2025,
author = {Wang, Hao and He, Kexin and Huo, Ruixue and Li, Weihan and Zhang, Shan and Jiang, Lu-Ju and Wu, Hao and Yu, Minhao and Jiang, Shu-Heng and Xue, Junli},
title = {MAGEA6 Engages a YY1‐Dependent Transcription to Dictate Perineural Invasion in Colorectal Cancer},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {25},
doi = {10.1002/advs.202501119}
}
EUVIMED